[A23-09] Selinexor (multiple myeloma, = 1 prior therapy) - Addendum to Commission A22-100
Last updated 16.03.2023
Project no.:
A23-09
Commission:
Commission awarded on 07.02.2023 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with multiple myeloma who have received at least one previous treatment
Result of dossier assessment:
Unchanged after addendum: added benefit not proven
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A22-100 | Selinexor (multiple myeloma, second line) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2023-03-16 A G-BA decision was published.
G-BA documents on this decision